Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950455 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes
A Phase 3 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT01950455: Clinical Trial Phase 3 study, sponsored by Navidea Biopharmaceuticals.
NCT01950455 is a Phase 3 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 13 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950455, a Phase 3 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[123I\]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
Interventions
- DRUG NAV5001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-11 |
| Est. Completion | 2018-01 |
| Phase | Phase 3 |
Why NCT01950455 stopped before completion
NCT01950455 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which NAV5001 is the first listed.
NCT01950455 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01950455 about?
NCT01950455 is a clinical study titled "Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes". This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of \[123I\]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.
What is the current status of trial NCT01950455?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2013-11. Estimated completion is 2018-01.
What interventions are being tested in trial NCT01950455?
The interventions under investigation include: NAV5001 (DRUG).
Who is sponsoring clinical trial NCT01950455?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01950455's enrollment target sits among peer trials
13 1984th of 2000 higher than 17 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia